Evidence map›Paper›PMID 41322199›Full record

ArticleMolecular therapy. Oncology2025

Pre-clinical evaluation of a potent and effective Pin1-degrading agent in pancreatic cancer.

Giulia Alboreggia, Tiane Li, Anne Marie Prentiss, Parima Udompholkul, Frank Xia, Tim Synold, Jun Wu, Mingye Feng, Mustafa Raoof, Maurizio Pellecchia

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Giulia AlboreggiaDivision of Biomedical Sciences, School of Medicine, University of California, Riverside, 900 University Avenue, Riverside, CA 92521, USA.
Tiane LiDepartment of Surgery, City of Hope, Duarte, CA 91010, USA.
Anne Marie PrentissDivision of Biomedical Sciences, School of Medicine, University of California, Riverside, 900 University Avenue, Riverside, CA 92521, USA.
Parima UdompholkulDivision of Biomedical Sciences, School of Medicine, University of California, Riverside, 900 University Avenue, Riverside, CA 92521, USA.
Frank XiaAnalytical Pharmacology Core, City of Hope, Duarte, CA 91010, USA.
Tim SynoldAnalytical Pharmacology Core, City of Hope, Duarte, CA 91010, USA.
Jun WuAnimal Tumor Model Core, City of Hope, Duarte, CA 91010, USA.
Mingye FengDepartment of Immuno-Oncology, City of Hope, Duarte, CA 91010, USA.
Mustafa RaoofDepartment of Surgery, City of Hope, Duarte, CA 91010, USA.
Maurizio PellecchiaDivision of Biomedical Sciences, School of Medicine, University of California, Riverside, 900 University Avenue, Riverside, CA 92521, USA.

Funding

Project 2U54CA285116 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI ERNEST MARTINEZ, Victoria L. Seewaldt · 2023 to 2026
$6.8M
Research EducationU54CA285114 · NCI · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI ERNEST MARTINEZ, Victoria L. Seewaldt · 2023 to 2026
$6.2M
NCI NIH HHS U54 CA285114NCI NIH HHS U54 CA285116
6 · The paper itself

Abstract

The peptidyl-prolyl isomerase protein Pin1 has been shown to contribute to cancer onset, development, and progression by regulating the function and stability of oncogenes and tumor suppressors, both in cancer cells and surrounding stromal cells. Hence, it has long been sought as a possible therapeutic target in oncology. However, further validation of Pin1 as a suitable target for novel therapeutic strategies requires the development of potent and effective pharmacological inhibitors, which are currently scarce. Very recently, we reported novel covalent Pin1 inhibitors that, acting as molecular crowbars, destabilize the protein

Indexed as

cancer-associated fibroblastsmolecular crowbarsMT: Regular IssuePDACPin1

Identifiers

PMID41322199
PMCPMC12657321

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.